JP2001278763A - Cariostatic agent - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a cariostatic agent comprising a substance safe for human bodies and available at a low cost as an active ingredient. SOLUTION: This cariostatic agent comprises a civet tincture as the active ingredient. The component for the oral cavity comprises the cariostatic agent. The civet is a secretion obtained from scent glands of Carnivora Viverridas such as Viverra civetta or Viverra zibetha and is widely conventionally known as an ingredient of a Chinese medicine and commercially available as the civet tincture. For example, the civet tincture can be prepared by dissolving the civet with ethanol under warming and carrying out the extraction.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to an anti-carious agent.

[0002]

2. Description of the Related Art Caries are generally called caries, and the causes thereof are considered as follows. Naturally, certain kinds of bacteria are adsorbed on teeth due to the interaction between the glycoprotein, which is a component in saliva, and the cell surface substance of bacteria resident in the oral cavity. This bacterium is a glucosyltransferase (hereinafter referred to as "G"), which is an enzyme secreted outside the cells.
Tase ”. ), Food-derived sucrose is denatured into a sticky polysaccharide, and adheres more firmly to the tooth surface. This is generally called plaque, and the attached bacteria metabolize sugars in the plaque and generate an acid as a metabolite thereof.
The acid demineralizes the enamel surface of the tooth and promotes dental caries. It is said that plaque causes not only caries, but also bad breath, and depending on its progress, periodontal disease, gingivitis, and even alveolar pyorrhea.

[0003]

An object of the present invention is to provide an anti-cariogenic agent which is available at a low cost and contains a substance which is safe for the human body as an active ingredient. A second object of the present invention is to provide an anti-cariogenic agent useful for preventing oral diseases such as bad breath, periodontal disease, gingivitis and alveolar pyorrhea by suppressing the formation of plaque. is there.

[0004]

SUMMARY OF THE INVENTION In view of the above circumstances, the present inventor has conducted intensive studies day and night in search of an anti-caries agent which is suitable for prevention of caries and periodontal disease and which is safe for the human body. However, they found that civet, which is used as a herbal medicine, has an effect of significantly preventing S. mutans and S. sobrinus from adhering to teeth, and confirmed that it was effective as an anti-carious agent. The present invention has been completed based on such findings.

That is, the present invention is an anti-caries agent containing civet as an active ingredient.

The present invention is also an oral composition (including food and drink) containing the above-mentioned anti-carious agent.

[0007]

BEST MODE FOR CARRYING OUT THE INVENTION Civet is a carnivorous civet (Carnivoridae) such as musk cats and Indian musk cats.
a Viverridas) is a secretion obtained from the incense gland. The civet has conventionally been widely known as a component of Chinese herbal medicine, and is commercially available as civet tincture. For example, civet tincture can be prepared by extracting civet by heating and dissolving it with ethanol.

[0008] The anti-caries agent of the present invention contains the above civet as an active ingredient, and is formulated as an ingredient of various oral compositions such as foods, quasi-drugs, and pharmaceuticals, and is used in the oral cavity. Can be effectively used to prevent the formation of glucan and plaque. The term "oral composition" used herein includes both those that are taken orally, such as food and drink, and those that are used in the mouth, such as toothpaste and mouthwash. Specific examples of the oral composition include various foods such as troches, chewing gums, candy, gummy candy, chocolate, juice, etc .; dentifrices (paste, liquid, powder solid),
Drugs or quasi-drugs such as mouth fresheners such as mouse sprays, chewing agents, lozenges, oral pasta, gargles, syrups; and oral cosmetics such as dentifrices, mouthwashes, mouth rinses it can. Preferably, foods such as troches, chewing gums and candy, and mouthwashes such as dentifrices, mouthwashes and mouth rinses can be mentioned. These forms and dosage forms are not particularly limited, and can be arbitrarily determined according to the type.

The application concentration of the anti-caries agent of the present invention can be appropriately selected and determined in consideration of various factors such as the type of oral composition and dilution in the mouth. Suitable concentrations are 0.0 civet per 100% by weight of the oral composition.
The range is 1 to 5% by weight, particularly 0.03 to 1% by weight.

The anti-caries agent of the present invention is known or may be known in the future as an antibacterial agent against S. mutans or S. sobrinus , as long as the effects of the present invention are not impaired. Anti-adhesion agent to surface or anti-GTase
It can also be compounded in combination with components such as an anti-caries agent or an anti-inflammatory agent.

[0011] The anti-caries agent of the present invention can be used in combination with a component usually blended in the oral composition, depending on the type of the oral composition to be applied.

For example, in the case of toothpaste, an abrasive such as dibasic calcium phosphate, calcium carbonate, insoluble sodium metaphosphate, amorphous silica, aluminum oxide, etc .; carboxymethylcellulose, hydroxyethylcellulose, alginate, carrageenan, gum arabic, polyvinyl alcohol, etc. Binders such as polyethylene glycol, sorbitol, glycerin, propylene glycol;
Sodium lauryl sulfate, sodium dodecylbenzene sulfonate, hydrogenated coconut fatty acid sodium monoglyceride monosulfate, sodium lauryl sulfoacetate,
Foaming agents such as sodium N-lauroyl sarcosinate, N-acyl glutamate, sucrose fatty acid esters and the like can be mentioned. Further, flavoring agents such as menthol and flavoring or sweetening agents, preservatives and the like which are usually used therefor can be used. Can be blended. In the case of mouthwashes such as mouthwashes and foods such as chewing gum, conventional ingredients can be used in combination. In addition, as a sweetener combined and used, those with low or no caries are preferable, and for example, D-xylose, xylitol, saccharin sodium, aspartame, trehalose and the like can be suitably mentioned.

Further, the anti-caries agent of the present invention includes lysozyme chloride, lytic enzyme, dextranase, mutanase, chlorhexidine, sorbic acid, alexidine, hinokitiol, cetylpyridinium, alkylglycine, alkyldiaminoethylglycine salt, monofluorophosphate Sodium, sodium fluoride, stannous fluoride, water-soluble primary or secondary phosphate, quaternary ammonium compound,
It can be used in combination with components such as sodium chloride.

[0014]

The present invention will be described in more detail with reference to the following Test Examples and Examples, which should not be construed as limiting the present invention. <Test Example> The anti-cariogenic effect of civet was evaluated by the plaque (fungus) adhesion suppression test described below. The plaque (bacteria) adhesion test was performed using a test tube instead of the tooth surface. (i) Streptococcus mutans plaque against bacteria (bacteria) adhesion prevention effect First, Streptococcus mutans bacteria MT8148 strain 1% overnight culture 30μl Bren heart infusion liquid medium containing (serotype c) (BHI medium) sucrose The sugar-containing BHI medium was added to 3 ml (test tube with a sterilized lid), and civet tincture (civet tincture or civet tincture-A: both manufactured by Nippon Powder Chemical Co., Ltd.) was mixed at various concentrations. The test tube was inclined at 30 ° and incubated at 37 ° C. for 18 hours. The above civet tincture is civet (trade name: Civetol: Nippon Powder Chemical Co., Ltd.) 50
g was dissolved by heating with about 900 ml of ethanol, and the obtained filtrate was adjusted to a final volume of 1000 ml with ethanol. 1 ml of this product corresponds to 500 mg of the crude drug. Civet tincture-A was obtained by adding about 11 times the amount of anhydrous ethanol to 50 g of civet (trade name: Sivetol: Nippon Shokubai Co., Ltd.), extracting the mixture by refluxing at about 80 ° C. for 1 hour, and filtering it while warm. The final volume of the filtrate is 1000 ml with ethanol
1 ml of this product is 100 m of the crude drug
g.

After culturing for 18 hours, the test tube was slowly rotated three times at an angle of 30 degrees, and the culture solution was slowly decanted into an empty test tube (sample 1). 3 ml of the above-mentioned 1% sucrose-containing BHI medium is placed in an empty test tube having bacteria adhered to the inside surface of the test tube, and the mixture is stirred by vortex to remove a part of the plaque (fungus) attached to the inside surface of the test tube. After washing and elution, the culture solution containing the plaque (bacteria) eluate was decanted into an empty test tube (sample 2). Then, 3 ml of 1% sucrose-containing BHI medium was again added to the obtained plaque (bacteria) attached test tube, the plaque (bacteria) firmly adhered to the inner surface of the test tube was scraped off with a spatula, and the solution was sampled. It was set to 3. Note that, of the above operations, the vortex stirring operation is based on the assumption that the mouth is rinsed. That is, sample 2 reflects the amount of bacteria that can be taken with a mouth rinse, and sample 3 reflects the amount of bacteria that cannot be taken with a mouth rinse.

Further, the amount of plaque (bacteria) contained in each sample solution was determined by measuring the turbidity (OD: absorbance 550 nm) of the solution. Next, the plaque (bacteria) adhesion rate was determined from the turbidity of the solution by the following formula, and the plaque (bacterium) adhesion-suppressing action of the civet was evaluated based on the adhesion rate (%).

[0017]

(Equation 1)

As a control, civet tincture was not added to the test tube (civet tincture concentration: 0 μl /
3 ml) Table 1 also shows the plaque adhesion rate when the experiment was performed in the same manner as described above.

[0019]

[Table 1]

(Ii) Inhibitory effect on plaque (bacteria) adhesion to Streptococcus sobrinus bacteria The plaque (bacterium) adhesion suppression test was also performed on Streptococcus sobrinus strain 6715 (serotype g ) in the same manner as (i) above. The effect of inhibiting plaque (bacteria) adhesion was evaluated.
Table 2 shows the results.

[0021]

[Table 2]

From the above results, it was found that civet has an effect of suppressing plaque adhesion and is an effective anti-carious agent.

[0023]

EXAMPLES Examples of application of the anti-caries agent of the present invention will be described below as examples. The unit of each prescription means part by weight unless otherwise specified. Example 1 Chewing gum Calcium carbonate 5.0 Civet tincture A 0.6 Gum base 30.0 Erythritol 10.0 Xylitol 40.0 Maltitol 14.0 Perfume 0.4 Total 100.00.

[0024]

Example 3 Sugar-Coated Tablet A mouthwash was prepared by coating 200 parts by weight of a tablet portion with 130 parts by weight of a sugar-coated portion.

[0026]

[0027]

[0028]

[0029]

[0030]

[0031]

[0032]

Example 10 Oral Pasta Liquid Paraffin 13.00 Cetanol 10.00 Glycerin 25.00 Sorbitan Monopalmitate 0.60 Polyoxyethylene Sorbitan Monostearate 5.00 Sodium Lauryl Sulfate 0.10 Benzotonium Chloride 0.10 Methyl Salicylate 0.10 Saccharin 0.20 Fragrance 0.25 Civet Tin A A 0.60 Water Residue Department Total 100.00

Continuing from the front page (72) Inventor: Kiyoko Yoshii 3-13-35, Mitsujinaminami, Yodogawa-ku, Osaka-shi, Osaka F-term (reference) 4C083 AA071 AA072 AA122 AB222 AB292 AB322 AB472 AC012 AC072 AC102 AC122 AC132 AC302 AC312 AC432 AC442 AC482 AC642 AC692 AC782 AC862 AD092 AD222 AD242 AD272 AD302 AD352 AD392 AD432 CC41 DD12 DD15 DD21 DD22 DD23 EE32 4C087 AA01 AA02 BB42 MA57 NA14 ZA67

Claims (2)

[Claims] 1. An anti-cariogenic agent comprising civet as an active ingredient. 2. An oral composition comprising the anti-cariogenic agent according to claim 1.